Revision History

Researchers at the 2025 and 2026 ASCO Annual Meetings presented several therapies targeting how tumors hide from the immune system — including the ERAP1 inhibitor GRWD5769, the fascin inhibitor NP-G2-044, and the bispecific T-cell engager tarlatamab — alongside chemo-alternative regimens that showed meaningful survival gains. But persistent gaps in clinical trial diversity, single-digit overall approval rates for oncology drugs, immunotherapy costs exceeding $100,000 per patient, and geographic concentration of trials in wealthy nations raise hard questions about who will benefit and when.